UAE launches first genomics trial to prevent Alzheimer’s
Groundbreaking study will use national genome data to identify high-risk individuals before symptoms develop and test preventive treatment
ABU DHABI, UAE (MNTV) — The United Arab Emirates has launched its first genomics-driven clinical trial aimed at preventing Alzheimer’s disease by identifying people at high genetic risk before symptoms appear.
The study is being led by M42’s Insights Research Organization and Solutions (IROS) in partnership with the Department of Health – Abu Dhabi and biotechnology company Halia Therapeutics. It marks a significant step in applying data from the Emirati Genome Programme to clinical care.
Researchers will evaluate HT-4253, an investigational therapy developed by Halia Therapeutics, in individuals who carry the APOE4 gene variant, one of the strongest known genetic risk factors for Alzheimer’s disease.
Eligible participants will be selected through targeted screening based on approved genomic eligibility criteria and under regulatory oversight.
According to Pharma Times, Dr. Noura Al Ghaithi, undersecretary of the Department of Health – Abu Dhabi, said the Emirati Genome Programme has become a strategic national resource that is helping transform healthcare through precision medicine and disease prevention.
She said the trial demonstrates how large-scale genomic research can be translated into practical medical applications that improve public health.
Alzheimer’s disease affects more than 55 million people worldwide, with the number of cases expected to nearly triple by 2050. Health authorities say the UAE is preparing for a growing burden of neurodegenerative diseases by investing in earlier detection and preventive treatment strategies.
The clinical trial is supported by the Emirati Genome Programme, which has sequenced more than 900,000 genomes.
Researchers say the database provides valuable insights into the prevalence of the APOE4 gene variant among Emirati and Arab populations, enabling the identification of high-risk individuals on an unprecedented scale.
The study will be conducted in Abu Dhabi, with patient data integrated through Malaffi, the emirate’s health information exchange platform.
Researchers say the initiative represents a major milestone in converting years of genomic investment into clinical practice while advancing precision medicine and personalized healthcare in the UAE.
We must take charge of our narrative. Research indicates that 92% of their Muslim coverage is negative. Help us change that.
Have Your Say!
Have you been affected by the issues raised in this story? Please share your experiences by emailing haveyoursay@soundvision.com.
Please include a contact number if you are willing to speak to a Muslim Network TV’s representative. You can also get in touch in the following ways:
Tweet: @MuslimNetworkTV
